Cystemustine

Cystemustine is a DNA inhibitor (a chloroethyl nitrosourea, CENU) . Cystemustine can cause DNA cross-linking, thereby inhibiting the proliferation of tumor cells. Cystemustine can also exert cytotoxic effects by interfering with the cell cycle, inducing cell re-differentiation, and altering phospholipid metabolism. Cystemustine exhibits high anti-tumor activity and a relatively short plasma half-life in mice. Cystemustine can be used for the study of various malignant tumors, including melanoma, glioma, renal cancer, head and neck cancer, and colorectal cancer, etc[1][2][3][4][5][6].

Product Specifications

CAS Number

[79955-36-5]

UNSPSC

12352211

Target

DNA Alkylator/Crosslinker; DNA/RNA Synthesis

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

CS(CCNC(N(N=O)CCCl)=O)(=O)=O

Molecular Formula

C6H12ClN3O4S

Molecular Weight

257.70

References & Citations

[1]Palmer B. Cystemustine INSERM. IDrugs. 1998 May;1 (1) :129-35. PMID: 18465517.|[2]Martineau-Pivoteau N, et al. Circadian rhythm in toxic effects of cystemustine in mice: relevance for chronomodulated delivery. Int J Cancer. 1996 Nov 27;68 (5) :669-74.|[3]Buchdahl C, et al. Melanoma-cell toxicity of cystemustine combined with O6-benzyl-N2-acetylguanosine. Melanoma Res. 1998 Apr;8 (2) :123-30. |[4]Demidem A, et al. Cystemustine induces redifferentiation of primary tumors and confers protection against secondary tumor growth in a melanoma murine model. Cancer Res. 2001 Mar 1;61 (5) :2294-300.|[5]Morvan D, et al. Melanoma tumors acquire a new phospholipid metabolism phenotype under cystemustine as revealed by high-resolution magic angle spinning proton nuclear magnetic resonance spectroscopy of intact tumor samples. Cancer Res. 2002 Mar 15;62 (6) :1890-7.